Kinevant Sciences

Kinevant Sciences is a clinical-stage biopharmaceutical company dedicated to treating rare autoimmune diseases with significant unmet need. Our lead candidate, namilumab, is a monoclonal antibody being developed for the treatment of sarcoidosis. Namilumab targets GM-CSF, a key pro-inflammatory cytokine and growth factor implicating in the pathogenesis of sarcoidosis and other inflammatory disorders. We plan to initiate a global Phase 2 clinical trial in the first half of 2022 evaluating namilumab in pulmonary sarcoidosis, which affects ~90% of all sarcoidosis patients.